Expression of cancer stem cell marker USP22 in laryngeal squamous cell carcinoma.
- Author:
Lijuan LI
1
;
Shuxin WEN
2
;
Binquan WANG
1
;
Wei GAO
1
;
Wen ZHANG
1
;
Xiaomin MENG
1
;
Lijuan YANG
1
;
Lingshuai KONG
1
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Squamous Cell; metabolism; pathology; Female; Head and Neck Neoplasms; metabolism; pathology; Humans; Laryngeal Mucosa; metabolism; Laryngeal Neoplasms; metabolism; pathology; Male; Middle Aged; Neoplasm Staging; Neoplastic Stem Cells; metabolism; Prognosis; Thiolester Hydrolases; metabolism
- From: Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2014;49(6):479-482
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression of cancer stem cell marker USP22 in laryngeal squamous cell carcinoma (LSCC) and clinical implications.
METHODSThe expression of USP22 was detected by immunohistochemistry in LSCC tissues of 64 cases and squamous epithelium tissues beside carcinoma of 26 cases (control). The correlation of USP22 expression with various clinicopathologic factors was evaluated with the single factor analysis.
RESULTSThe expression levels of USP22 in LSCC and control were 57.8% and 19.2% (P < 0.05). Clinicopathological analysis showed that USP22 expression level had a relationship with clinical stage, T stage, and lymph node metastasis (P < 0.05), but not with gender, age, smoking and differentiation (P > 0.05). Survival analysis showed that patients with high USP22 expression had significantly poorer outcome compared with patients with low USP22 expression. The survival was related to clinical stage, T stage, and lymph node metastasis, but not with age, sex, and smoking (P > 0.05).
CONCLUSIONSThe expression of USP22 is significantly increased in LSCC, which correlates with the malignant degree, invasion, metastasis and prognosis of LSCC. USP22 may be served as a new candidate molecular marker and therapeutic target of LSCC.
